Poster No. 415

# Epidemiological Evaluation of Antibiotic Resistance and Subsequent Effect on Healthcare Resource Utilization among Subjects with *Pseudomonas aeruginosa* Infections in Italy

## Matteo Bassetti<sup>1</sup>, Antonio Cascio<sup>2</sup>, Annamaria Cattelan<sup>3</sup>, Roberto Cauda<sup>4</sup>, Francesco Menichetti<sup>5</sup>, Nicola Petrosillo<sup>6</sup>, Carolina Rescigno<sup>7</sup>, Carlo Tascini<sup>8</sup>, Antonio Vena<sup>1</sup> e Pierluigi Viale<sup>9</sup>;

1. IRCCS Policlinico San Martino Hospital, Genoa, Italy; 2. Policlinico Giaccone Hospital, AORN dei Colli, Naples, 1. IRCCS, Rome, Italy; 3. Azienda Ospedaliero Universitario "Agostino Gemelli" IRCCS, Rome, Italy; 3. Azienda Ospedaliero Universitaria Pisana Cisanello, Pisa, Italy; 3. Azienda Ospedaliero Universitaria Pisana Cisanello, Pisa, Italy; 3. Azienda Ospedaliero Universitario "Agostino Gemelli" IRCCS, Rome, Italy; 3. Azienda Ospedaliero Universitario "Agostino Gemelli" IRCCS, Rome, Italy; 3. Azienda Ospedaliero Universitario "Agostino Gemelli" IRCCS, Rome, Italy; 3. Azienda Ospedaliero Universitario "Agostino Gemelli" IRCCS, Rome, Italy; 3. Azienda Ospedaliero Universitario "Agostino Gemelli" IRCCS, Rome, Italy; 4. Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Rome, Italy; 5. Azienda Ospedaliero Universitario "Agostino Gemelli" IRCCS, Rome, Italy; 5. Azienda Ospedaliero Universitario "Agostino Gemelli" IRCCS, Rome, Italy; 5. Azienda Ospedaliero Universitario "Agostino Gemelli" IRCCS, Rome, Italy; 5. Azienda Ospedaliero Universitario "Agostino Gemelli" IRCCS, Rome, Italy; 5. Azienda Ospedaliero Universitario "Agostino Gemelli" IRCCS, Rome, Italy; 5. Azienda Ospedaliero Universitario "Agostino Gemelli" IRCCS, Rome, Italy; 5. Azienda Ospedaliero Universitario "Agostino Gemelli" IRCCS, Rome, Italy; 5. Azienda Ospedaliero Universitario "Agostino Gemelli" IRCCS, Rome, Italy; 5. Azienda Ospedaliero Universitario "Agostino Gemelli" IRCCS, Rome, Italy; 7. Cotugno Versitario "Agostino Gemelli" IRCCS, Rome, Italy; 7. Cotugno Ag Italy 8. Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy 9. Policlinico Sant'Orsola Malpighi, Bologna, Italy

## Background

- The susceptibility rates for antimicrobial agents for Gram negatives pathogens (GNP) vary across Europe, and Italy shows one of the highest multidrug resistant (MDR)/ extensively Drug Resistant (XDR) GNP rates among the Western European countries.
- To the best of our knowledge, there is a lack of data specifically addressing the epidemiology of MDR/XDR *P.aeruginosa* (PA) strains isolated from patients with nosocomial pneumonia infections (NP), complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs) admitted to Italian hospitals.
- This study aims to evaluate the rate of MDR/XDR PA infections as well as health care resources utilization (intensive care unit stays, prolonged hospital stay) in NP, cUTI, cIAI caused by PA.

## Results

#### CLINICAL CHARACTERISTICS OF PATIENTS WITH PSEUDO-**MONAS AERUGINOSA INFECTIONS**

- Overall, a total of **95** patients with a definite microbiological diagnosis of nosocomial infection due to PA were enrolled and followed prospectively.
- Clinical and epidemiological information of the study population is shown in **Table 1**.
- Overall, 51/95 patients (53.7%) had nosocomial pneumonia, 33/95 (34.7%) cUTIs and 11/95 (11.5%) cIAIs.
- Almost **one-third of patients (28.4%)** reported either **MDR or XDR** *P.aeruginosa* infection (Figure 2).
- Clinical characteristics of patients with MDR/XDR *P.aeruginosa* infections are reported in **Table 1**.






Table 1. comial infe

#### Characte

Age, mea

Male sex,

#### Underlyin

Diabet Chron Heart d Solid tu Liver dis

Type of no

Nosocon Complic

Complie

Predispo

Invasiv Previou Surger Previou Total p

\* A few patients had missing values



Material and Methods					
• Setting: Multicenter prospective study conducted in 8 large t					

- Study period: June 2018-February 2020.
- **Design:** Prospective observational analysis from hospital medical chart reviews
- During the study period the investigators conducted a daily evaluation of microbiological results obtained from respiratory, urinary and intra-abdominal samples. • Inclusion criteria: Patients aged over 18 years with a clinical diagnosis of NP, cUTI or cIAI due to PA.
- Definition: MDR PA: non-susceptibility to at least one agent in three or more antimicrobial categories. XDR PA: non-susceptibility to at least one agent in all but two or fewer antimicrobial categories.

L.	Demographics and	Clinical	Characteristics	of the	95 patients	with	noso-
fe	ctions due to PA						

# **D**Veek

### ching hospitals in Italy (Figure 1).

• The impact of PA infections on the health care resources utilization metrics included *i*) hospital length of stay (LOS) and *ii*) intensive care unit (ICU) LOS.

#### HEALTHCARE RESOURCE UTILIZATION

alth care resource utilization, stratified by patients with and without DR/XDR nosocomial infections, is reported in **Table 2**.

erall, in our study population, median hospital LOS and ICU LOS re 42.0 (IQR=39.0) and 15.5 (IQR=37.0) days, respectively.

ere was a statistically significant longer median hospital LOS for pants with MDR/XDR infections compared to non MDR/XDR PA infecns (53.0 vs. 36.5 days, p=0.04).

I LOS also trended towards being longer for patients with MDR/XDR ections compared to those with non-MDR/XDR infections (25.5 vs. days). However, such difference was not statistically significant.

### Variables

#### **Overall study po** (n=95)

Hospital LOS, m ICU LOS, media

#### **Patients with NF** Hospital LOS, n

ICU LOS, media

### **Patients with cl** Hospital LOS, m


ICU LOS, media

#### **Patients with c** Hospital LOS, n ICU LOS, medi

## nclusions

DR/XDR isolates were prevalent among Italian patients with nosocomial infections due to *Pseudomonas aeruginosa* 

verall, the present study suggests a positive correlation between having MDR-XDR *Pseudomonas aeruginosa* nosocomial infections (NP, cUTI, and cIAI) and increased healthcare resource utilization that require further attention from a disease management perspective.



**Table 2.** Health care resource utilization by presence of MDR/XDR, in strata of type of infection

	MDR/XDR (n=27)	No MDR/XDR (n=68)	P-value
opulation			
median (IQR) an (IQR)	53.0 (47.0) 25.5 (41.5)	36.5 (35.5) 13.5 (37.0)	<b>0.04</b> 0.10
P (n=51) median (IQR) an (IQR)	33.0 (38.0) 42.0 (53.0)	25.5 (37.0) 28.0 (37.0)	0.59 0.40
<b>UTI (n=33)</b> median (IQR) an (IQR)	65.0 (120.0) 25.5 (17.7)	41.0 (30.0) 4.5 (6.5)	<b>0.02</b> 0.11
<b>IAI (n=11)</b> median (IQR) an (IQR)	61.0 (10.0) 12.0 (-)	35.5 (21.0) 3.5 (1.0)	0.12 0.54